...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
【24h】

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

机译：曲妥珠单抗的静脉内和皮下制剂，以及曲妥珠单抗生物综合生线：对临床实践的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Trastuzumab was originally approved as an intravenous (IV) formulation but has since been developed for subcutaneous (SC) administration for patients with HER2-positive breast cancer. Both formulations demonstrate generally comparable pharmacological and clinical profiles. Therefore, when deciding between treatment options, factors such as the route of administration, patient preference, value and cost must be considered. Studies comparing IV with SC trastuzumab indicate that each formulation offers unique advantages to patients depending on their individual needs. Concurrent with the development of SC trastuzumab, IV trastuzumab biosimilars comprise another treatment option that, in view of their reduced cost, might improve patient access and increase cost-effectiveness for healthcare providers and payers. In this review, we seek to raise awareness of the current options available for trastuzumab so that healthcare providers can optimally treat patients according to their individual situations and preferences.
机译：Trastuzumab是一种生物学治疗，用于治疗人表皮生长因子受体2（HER2） - 阳性乳腺癌和转移性胃癌。 Trastuzumab最初批准为静脉注射（IV）配方，但由于SER2阳性乳腺癌患者的皮下（SC）给药以来已经开发出来。两种制剂都展示了一般可比较的药理学和临床曲线。因此，当决定治疗方案之间时，必须考虑诸如给药途径，患者偏好，价值和成本的因素。与SCRastuzumab的IV进行比较的研究表明，每个配方对患者提供独特的优势，具体取决于他们的个人需求。随着SCRastuzumab的发展并发，IV曲妥珠单抗的生物纤维单模包括另一个治疗选项，鉴于其成本降低，可能会改善患者访问，并提高医疗保健提供者和付款人的成本效益。在这篇综述中，我们寻求提高对Trastuzumab可用的当前选择的认识，以便医疗保健提供者可以根据个人情况和偏好最佳地治疗患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号